close
To:

From:

Current Advances

Regulus announces first demonstration of proof-of-concept in patients with hepatitis C virus (HCV)

Regulus reported today that a single 2 mg/kg dose of RG-101, an anti-miR targeting microRNA-122 ("miR-122") in patients with hepatitis C virus (HCV), demonstrated a mean viral load reduction of 4.1 log10 at Day 29 in 14 patients with consistent effects across multiple HCV genotypes.

For the complete release click here

RG-101 is the first drug to enter clinical development at Regulus, and the first drug to enter clinical development that incorporates Isis' antisense technology to target a microRNA. RG-101 was discovered using the Isis antisense technology platform and incorporates a galNac-conjugate, which confers the ability to distribute more drug to its target tissue, the liver.

RG-101 is the most advanced program in Regulus' pipeline and the data reported today is the first demonstration of activity in patients with HCV. The target of RG-101, miR-122, is the most abundant microRNA in the liver. miR-122 is a critical host factor for survival and replication of all known HCV genotypes. The duration of action observed for RG-101 supports the potential for a once-a-month dosing regimen.

Regulus was cofounded by Isis and Alnylam to focus on the discovery, development and commercialization of microRNA-targeted therapeutics. Because microRNAs may act as master regulators of the genome, affecting the expression of microRNAs provides a broad therapeutic opportunity. Regulus is addressing therapeutic opportunities that arise from alterations in microRNA expression.

Regulus' initial public offering was in 2012. Isis is currently the top Regulus shareholder.

About Isis

We know that sick people depend on us, and we have the technology to change the way diseases are treated.

Learn More

Mission & Values

Our mission is to provide antisense drugs to patients with significant unmet medical needs.

Learn More